Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on February 26, 2021, with the report date of March 5, 2021. The filing reports a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) approved the Argus 2s Retinal Prosthesis System on February 26, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance metrics.
Material Changes
- Regulatory Approval: The FDA approved the Argus 2s, a redesigned external hardware system (glasses and video processing unit) for use with previously implanted Argus II systems to treat retinitis pigmentosa (RP).
- Approval Conditions: The approval is granted under a Humanitarian Device Exemption (HDE) and is contingent upon periodic reporting to the CDRH, prescription-only use, and supervision by an Institutional Review Board (IRB).
- Strategic Pivot: The Argus 2s is expected to serve as the external system for the next-generation Orion Visual Cortical Prosthesis System currently under development.
Guidance, Outlook, and Risks
- Production Status: A decision on when or if to begin production of the Argus 2s hardware is pending the completion of a planned business combination with Pixium Vision.
- Management Commentary: Should the business combination with Pixium Vision be completed, the new management team will evaluate the best path forward for the Argus 2s and other products in development.
- Risks: Commercialization and production timelines are currently uncertain and dependent on the outcome of the ongoing merger discussions.
Investor Verification Checklist
- Verify the status and expected closing date of the business combination with Pixium Vision.
- Confirm the specific requirements and reporting obligations associated with the Humanitarian Device Exemption (HDE).
- Monitor future announcements regarding the production timeline for the Argus 2s hardware.
- Review the attached press release (Exhibit 99.1) for additional details on the FDA approval scope.